全文获取类型
收费全文 | 5766篇 |
免费 | 503篇 |
国内免费 | 330篇 |
专业分类
耳鼻咽喉 | 69篇 |
儿科学 | 116篇 |
妇产科学 | 127篇 |
基础医学 | 670篇 |
口腔科学 | 102篇 |
临床医学 | 660篇 |
内科学 | 1076篇 |
皮肤病学 | 40篇 |
神经病学 | 234篇 |
特种医学 | 145篇 |
外国民族医学 | 2篇 |
外科学 | 595篇 |
综合类 | 948篇 |
预防医学 | 355篇 |
眼科学 | 121篇 |
药学 | 522篇 |
1篇 | |
中国医学 | 295篇 |
肿瘤学 | 521篇 |
出版年
2024年 | 18篇 |
2023年 | 55篇 |
2022年 | 181篇 |
2021年 | 223篇 |
2020年 | 178篇 |
2019年 | 194篇 |
2018年 | 177篇 |
2017年 | 157篇 |
2016年 | 171篇 |
2015年 | 282篇 |
2014年 | 339篇 |
2013年 | 281篇 |
2012年 | 439篇 |
2011年 | 430篇 |
2010年 | 308篇 |
2009年 | 256篇 |
2008年 | 292篇 |
2007年 | 323篇 |
2006年 | 316篇 |
2005年 | 315篇 |
2004年 | 183篇 |
2003年 | 187篇 |
2002年 | 182篇 |
2001年 | 156篇 |
2000年 | 139篇 |
1999年 | 147篇 |
1998年 | 79篇 |
1997年 | 91篇 |
1996年 | 55篇 |
1995年 | 42篇 |
1994年 | 60篇 |
1993年 | 41篇 |
1992年 | 43篇 |
1991年 | 38篇 |
1990年 | 28篇 |
1989年 | 29篇 |
1988年 | 42篇 |
1987年 | 28篇 |
1986年 | 19篇 |
1985年 | 18篇 |
1984年 | 10篇 |
1983年 | 4篇 |
1982年 | 6篇 |
1981年 | 7篇 |
1979年 | 5篇 |
1978年 | 4篇 |
1977年 | 3篇 |
1975年 | 3篇 |
1970年 | 3篇 |
1962年 | 3篇 |
排序方式: 共有6599条查询结果,搜索用时 31 毫秒
161.
Background:The efficacy of alfentanil supplementation for the sedation of bronchoscopy remains controversial. We conduct a systematic review and meta-analysis to explore the influence of alfentanil supplementation on the sedation during bronchoscopy.Methods:We search PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through December 2019 for randomized controlled trials (RCTs) assessing the effect of alfentanil supplementation versus placebo for the sedation during bronchoscopy. This meta-analysis is performed using the random-effect model.Results:Five RCTs are included in the meta-analysis. Overall, compared with control group for bronchoscopy, alfentanyl supplementation is associated with significantly reduced coughing scores (Std. MD = –0.55; 95% CI = –0.96 to –0.14; P = 0.009) and dose of propofol (Std. MD = –0.34; 95% CI = –0.64 to –0.04; P = 0.03), but reveals the increase in hypoxemia (RR = 1.56; 95% CI = 1.17 to 2.08; P = 0.002).Conclusions:Alfentanyl supplementation benefits to reduce coughing scores and dose of propofol for bronchoscopy, but increases the incidence of hypoxemia. The use of alfentanyl supplementation for bronchoscopy should be with caution. 相似文献
162.
BackgroundHyperphosphatemia and anemia, which are common complications of chronic kidney disease (CKD), can independently contribute to cardiovascular events. Several previous studies have found that the iron-based phosphate binder, ferric citrate (FC), could be beneficial to both hyperphosphatemia and anemia.MethodsRelevant literature from PUBMED, EMBASE, the Cochrane Central Register of Controlled Trials (CCRCT) and MEDLINE databases were searched up to 21 February 2022, in order to conduct a meta-analysis to investigate the efficacy, safety and economic benefits of ferric citrate treatment in CKD patients with hyperphosphatemia and anemia. The meta-analysis was conducted independently by two reviewers using the RevMan software (version 5.3).ResultsIn total, this study included 16 randomized clinical trials (RCT) involving 1754 participants. The meta-analysis showed that ferric citrate could significantly reduce the serum phosphorus in CKD patients compared to the placebo control groups (MD −1.76 mg/dL, 95% CI (−2.78, −0.75); p = 0.0007). In contrast, the difference between ferric citrate treatment and active controls, such as non-iron-based phosphate binders, sevelamer, calcium carbonate, lanthanum carbonate and sodium ferrous citrate, was not statistically significant (MD − 0.09 mg/dL, 95% CI (−0.35, 0.17); p = 0.51). However, ferric citrate could effectively improve hemoglobin levels when compared to the active drug (MD 0.43 g/dL, 95% CI (0.04, 0.82); p = 0.03) and placebo groups (MD 0.39 g/dL, 95% CI (0.04, 0.73); p = 0.03). According to eight studies, ferric citrate was found to be cost-effective treatment in comparison to control drugs. Most of the adverse events (AE) following ferric citrate treatment were mild at most.ConclusionCollectively, our review suggests that iron-based phosphate binder, ferric citrate is an effective and safe treatment option for CKD patients with hyperphosphatemia and anemia. More importantly, this alternative treatment may also less expensive. Nevertheless, more scientific studies are warranted to validate our findings. 相似文献
163.
目的 :测定 10个男性健康者 11个时间点盐酸雷尼替丁泡腾颗粒剂的血药浓度及其药物动力学参数。方法 :10名男性健康志愿者口服盐酸雷尼替丁泡腾颗粒剂 ,采用HPLC法测定人血清中药物浓度并进行其药物动力学的研究。以ALLTIMAC18为固定相 ,0 .0 2mol·L 1磷酸二氢钾溶液 甲醇 (70 :30 )为流动相 ,检测波长为 32 0nm。结果 :泡腾颗粒剂血药浓度曲线均符合二室模型。其主要药物动力学参数 :Tpeak为 (1.96± 0 .5 5 )h ,Cmax为 (6 6 5± 2 13) μg·L 1,AUC为 (345 2± 6 0 1)h·μg·L 1。结论 :结果表明本法提取简便 ,灵敏度高 ,准确度高 相似文献
164.
An-te Ou Jia-xin Zhang Yue-fei Fang Rong Wang Xue-ping Tang Peng-fei Zhao Yu-ge Zhao Meng Zhang Yong-zhuo Huang 《Acta pharmacologica Sinica》2021,42(11):1913-1920
Sepsis is a dysregulated immune response to infection and potentially leads to life-threatening organ dysfunction, which is often seen in serious Covid-19 patients. Disulfiram (DSF), an old drug that has been used to treat alcohol addiction for decades, has recently been identified as a potent inhibitor of the gasdermin D (GSDMD)-induced pore formation that causes pyroptosis and inflammatory cytokine release. Therefore, DSF represents a promising therapeutic for the treatment of inflammatory disorders. Lactoferrin (LF) is a multifunctional glycoprotein with potent antibacterial and anti-inflammatory activities that acts by neutralizing circulating endotoxins and activating cellular responses. In addition, LF has been well exploited as a drug nanocarrier and targeting ligands. In this study, we developed a DSF-LF nanoparticulate system (DSF-LF NP) for combining the immunosuppressive activities of both DSF and LF. DSF-LF NPs could effectively block pyroptosis and inflammatory cytokine release from macrophages. Treatment with DSF-LF NPs showed remarkable therapeutic effects on lipopolysaccharide (LPS)-induced sepsis. In addition, this therapeutic strategy was also applied to treat ulcerative colitis (UC), and substantial treatment efficacy was achieved in a murine colitis model. The underlying mode of action of these DSF-LF-NPs may contribute to efficiently suppressing macrophage-mediated inflammatory responses and ameliorating the complications caused by sepsis and UC. As macrophage pyroptosis plays a pivotal role in inflammation, this safe and effective biomimetic nanomedicine may offer a versatile therapeutic strategy for treating various inflammatory diseases by repurposing DSF. 相似文献
165.
目的 了解珠海市人民医院2009~2010年住院患者常见的菌群分布及其耐药性,为细菌性感染的诊治提供参考依据.方法 用生物梅里埃公司的ATB鉴定系统进行菌种鉴定和药敏试验,用ATBPLUS VER3.0软件统计分析结果.结果 2009~2010年共分离出革兰阴性杆菌3 032株,其中铜绿假单胞菌占29.55%,肺炎克雷伯菌占33.44%,大肠埃希菌占27.51%,阴沟肠杆菌占5.80%,其他革兰阴性杆菌占3.70%.铜绿假单胞菌耐药率高于60%的抗菌药物有头孢噻吩、头孢噻肟、头孢西丁.肺炎克雷伯菌对美罗培南、亚胺培南、头孢吡肟、阿米卡星菌、妥布霉素、哌拉西林/三唑巴坦敏感.大肠埃希菌对第三代头孢菌素、氟喹诺酮类的耐药率增高,对亚胺培南、美罗培南、阿米卡星敏感,对哌拉西林/三唑巴坦、头孢他啶及奈替米星较敏感.阴沟肠杆菌呈多重耐药.结论 该地区常见革兰阴性杆菌的构成比及耐药率和国内其他地区有一定的差异,且细菌多重耐药情况更为严重. 相似文献
166.
目的:探讨眼底炫彩成像(MCI)联合光相干断层扫描成像(OCT)在视网膜动脉阻塞(RAO)的快速诊断及分类中的应用。方法:对本院2018-02/2020-07诊断为RAO的患者19例19眼进行回顾性研究。所有患者在经过眼科检查后确诊为RAO,均为单眼发病,其中视网膜中央动脉阻塞(CRAO)13眼,视网膜分支动脉阻塞(BRAO)5眼,睫状视网膜动脉残留的CRAO 1眼。所有患者行最佳矫正视力、裂隙灯、OCT、MCI、FFA及视野检查及分析。结果:经裂隙灯检查,12眼(63%)出现瞳孔对光反射迟钝或消失,16眼(84%)可发现全部或部分后极部视网膜苍白水肿,10眼(53%)可发现视网膜动脉变细。行FFA检查的患者为10例(53%),其余9例未行检查,其中6例患有严重的系统性疾病,2例拒绝检查、1例有药物过敏史。所有患者经MCI及OCT检查可发现特征性眼底表现,OCT特征性改变为弥漫性内层视网膜反射增强与MCI图像绿色缺血区域形成严密的一对一关系。结论:联合MCI及OCT检查可快速确诊RAO,而且结合两者的图像特征可更精确辨认出视网膜缺血区域,有助于疾病分类及预后判断。 相似文献
167.
“临床早期接触”对医学生关怀能力养成的效果分析——以汕头大学医学院“医者之心 《医学教育管理》2022,8(1):87-94
目的探讨医者之心(HEART)课程中“临床早期接触社会实践环节”对关怀能力养成的效果,对该课程纳入“临床早期接触”的教学设计做小结。方法编纂临床早期接触中的“隐性课程”体验问卷,对参加医者之心(HEART)课程的临床早期接触社会实践环节的学生进行事后访问及问卷调查,以此评估“隐形课程”对医学生关怀能力养成的初步情况。 结果医学实习生对各种具有隐性课程内涵举措的各个维度对其关怀能力培育的帮助,均呈偏正向的态度。“带教教师教学示范”“关怀展现”“专业胜任能力对学生关怀能力影响”这3个构面的强弱程度,会因“学生临床早期接触时长”“带教教师年资”“临床早期接触过程满意程度”的不同而呈现显著差异。结论“临床早期接触各类组织形式”对第一次进入临床体验的医学生关怀能力认知有重要影响,典范学习及同伴影响对医学生关怀能力认知有正向影响。 相似文献
168.
Yuanqiang Li Yunsheng Ou Yong Zhu Zenghui Zhao Bin He Shuai Xu Haoyang Yu 《Journal of orthopaedic science》2021,26(4):622-628
BackgroundBone mineral density (BMD) may be an important factor affecting the clinical outcomes after total knee arthroplasty (TKA). However, further information regarding BMD in postoperative pain relief is not present yet. This study aims to gain further insight into the predictive significance of BMD in postoperative pain relief in knee osteoarthritis (KOA) patients after TKA.Methods156 KOA patients treated by TKA were included in this study. Visual analogue scale (VAS) was used to measure the pain intensity in patients within one year after TKA. The patients were divided into good pain relief group (the improvement of VAS ≥ 3) and poor pain relief group (the improvement of VAS < 3). BMD and other clinical characteristics were also collected. Logistic regression analysis and receiver operating characteristic curve (ROC curve) were used to evaluate the predictive significance of BMD. Subgroup analysis was used to compare the difference of postoperative pain between High BMD group and Low BMD group extra.Results34 (21.8%) patients had poor pain relief after TKA. Logistic regression analysis indicated that age, BMD, preoperative hospital for special surgery (HSS) scores, preoperative VAS score and postoperative posterior slope angles (PSA) were the risk factors of poor pain relief (P < 0.05). Using BMD as a predictor, the optimum cut-off value of poor pain relief was T-level = ?3.0 SD in the ROC curve, where sensitivity and specificity were 73.5% and 83.7%, respectively. Based on this cut-off value, obvious pain relief was observed in the High BMD group compared with Low BMD group from the 6th month after TKA in the subgroup analysis (P < 0.05).ConclusionsBMD is an effective predictor for postoperative pain relief in KOA patients after TKA, and the poor pain relief should be fully considered especially when BMD T-level ≤ ?3.0 SD. 相似文献
169.
170.